Hyderabad: CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma Ltd, has obtained
marketing authorisation from UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for
Zefylti, its filgrastim biosimilar version.Earlier this year, in February, the European Commission (EC) has granted marketing authorization in the European Union (EU) for Zefylti, to CuraTeQ Biologics s.r.o.., as previously reported by Medical Dialogues.This is CuraTeQ’s second
biosimilar to be approved by MHRA after the approval of Bevqolva in December 2024.Zefylti is intended for the treatment of neutropenia and the mobilisation of peripheral progenitor cells (PBPCs).Read also: Aurobindo Pharma arm gets marketing authorisation for Zefylti in EUCuraTeQ Biologics Private Limited, a wholly owned subsidiary of Aurobindo Pharma Limited, is
a global biopharmaceutical company headquartered in Hyderabad, India. It is focused on developing biosimilars for the treatment of various
cancers and autoimmune diseases. CuraTeQ’s pipeline consists of fourteen biosimilars, primarily
targeting the immunology and oncology segments. It has end-to-end capabilities in producing a full
range of products from bulk drug substance to fill-finish and packaged drug products.Read also: Aurobindo Pharma gets USFDA final, tentative nod for different strengths of deep vein thrombosis drug RivaroxabanIts parent company, Aurobindo Pharma Limited, is an integrated global pharmaceutical company headquartered in
Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic
pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in
over 150 countries.
The company has 30+ manufacturing and packaging facilities that are approved by leading regulatory
agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC,
Brazil ANVISA. The Company’s product portfolio is spread over seven major therapeutic/product
areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and AntiAllergic, supported by a strong R&D set-up.Read also: Aurobindo Pharma arm CuraTeQ Biologics gets positive opinion for breast cancer drug Dazublys from EMA